A 6-Week Study Of PF-05175157 In Type 2 Diabetes Mellitus

PHASE2TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

PF-05175157

PF-05175157 will be administered at 200 mg twice a day for 43 days.

DRUG

Placebo

Placebo tablets matched to PF-05175157 will be administered twice a day for 43 days.

Trial Locations (1)

Profil Institute for Clinical Research, Inc., Chula Vista